Welcome to the Catasys On Healthcare Blog
Substance dependence drives significant health care costs for payors through a combination of factors that include acute inpatient utilization and unaddressed co-morbidities. The Substance Dependence problem is pervasive, largely untreated and costly. Stay informed on these topics by visiting our blog periodically. You can also sign up for the Catasys On Healthcare Newsletter to receive the latest in health care news. » Sign Up for Newsletter
Drug Seeking Behavior in ER Doubles, Feeds Growing Addiction to Pain Pills -- Emergency rooms continue to become a major resource for pain medication addicts; By MIKAELA CONLEY, ABC News Medical Unit -- Oct. 28, 2010» More
Catasys On Healthcare September 2010 Newsletter This edition of the Catasys newsletter outlines 8 drivers impacting cost savings from your substance dependent population. Surprisingly, national averages show $160 million in claims are incurred by substance dependent members in a 1 million member health plan. The majority of these costs are medical, driven by the consequences of substance abuse (and are mitigated if the substance abuse is successfully addressed).» More
For every 1 million members in a health plan, approximately $160 million in claims are incurred by members diagnosed with Substance Dependence. Most health plans have realistic cost savings opportunities in the millions of dollars. Our Medical Economics group can demonstrate specific savings opportunities for health plans with respect to both medical and behavioral costs. The OnTrak program addresses many of the challenges experts highlight within the existing treatment paradigm for substance dependence. Specifically, OnTrak: » More
LOS ANGELES--(BUSINESS WIRE) -- Sep. 17, 2009 --
Catasys, Inc. announced today that the Company has entered into a three
year agreement with Ford® Motor Company to provide the OnTrak
integrated substance dependence solution to Ford’s hourly employees in
Michigan enrolled in the National PPO and who meet certain criteria.
Eligible employees struggling with alcoholism, stimulant and opiate
dependence will be covered under the program, which contains medical
interventions, psychosocial therapy and care coaching components across
52 weeks. The Company will conduct direct outreach to enroll qualified
members, and will also work with UAW-Ford and Ford’s EAP program to
ensure the most beneficial treatment pathway for members. Contractual
revenues from the agreement are based on a combination of monthly fees
for the member population for Catasys, with additional monthly fees for
members enrolled into the Catasys program. Operational implementation is
expected to begin shortly, and the program is anticipated to launch in
the fourth quarter of 2009.
“We are pleased by the level of support we received from UAW-Ford and Ford’s management personnel,” said Rick Anderson, Catasys’ President and COO. “We have realigned our company and developed Catasys for the managed care market, and it is rewarding to have a new agreement that further publicly validates our product and business model. Ford’s desire to improve employee care and productivity demonstrates a significant opportunity for health plans to provide their customers the Catasys solution.”
Various studies, research and other resources demonstrate that:
» More
Randomized, Stratified, Double-Blind, Placebo-Controlled Trial of Flumazenil and Gabapentin for the Treatment of Alcohol Dependence Published in the Journal of Clinical Psychopharmacology, August 2009; 29(4):334-342. The OnTrak Medical Treatment Program achieved a significant reduction in use and cravings among members with symptoms of alcohol withdrawal (>6 CIWA) when compared to placebo.
Among members with more symptoms of alcohol withdrawal, the Prometa group experienced:» More